Traws Pharma, Inc.

NasdaqCM:TRAW Stock Report

Market Cap: US$40.6m

Traws Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of TRAW?
Owner TypeNumber of SharesOwnership Percentage
Institutions49,7921.65%
Private Companies65,8042.17%
Individual Insiders71,4212.36%
VC/PE Firms605,53120%
General Public2,233,00673.8%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 260.1%.

Top Shareholders

Top 25 shareholders own 26.2% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
20%
OrbiMed Advisors LLC
605,531US$8.1m0%0.1%
2.17%
Viriom Inc.
65,804US$883.1k0%no data
1.66%
Nikolay Savchuk
50,083US$672.1k31.5%no data
0.88%
The Vanguard Group, Inc.
26,722US$358.6k-5.5%no data
0.48%
Iain Dukes
14,662US$196.8k450%no data
0.33%
BlackRock, Inc.
9,956US$133.6k0.01%no data
0.3%
Geode Capital Management, LLC
8,963US$120.3k0%no data
0.099%
Steven Fruchtman
2,992US$40.2k-28.6%no data
0.069%
Bank of America Corporation, Asset Management Arm
2,085US$28.0k26,000%no data
0.052%
Mark Guerin
1,571US$21.1k0.06%no data
0.028%
James Marino
853US$11.4k0%no data
0.024%
Morgan Stanley, Investment Banking and Brokerage Investments
729US$9.8k-0.14%no data
0.022%
Viren Mehta
669US$9.0k0%no data
0.021%
UBS Asset Management AG
630US$8.5k-84%no data
0.014%
Mark Gelder
419US$5.6k0%no data
0.013%
Tower Research Capital Europe Limited
379US$5.1k171%no data
0.0068%
Vermillion & White Wealth Management Group LLC
205US$2.8k0%no data
0.0045%
Mary Shoemaker
136US$1.8k0.74%no data
0.0021%
Group One Trading LP, Asset Management Arm
64US$860.80%no data
0.0018%
Merrill Lynch & Co. Inc., Banking Investments
53US$710.60%no data
0.00089%
Jerome Groopman
27US$361.40%no data
0.0003%
Jack Stover
9US$121.812.5%no data
0.00007%
Pacific Capital Wealth Advisors, Inc.
2US$28.40%no data
0.00003%
Mehta Partners LLC
1US$12.20%100.0%
0.00003%
Securities America Advisors, Inc.
1US$12.20%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 17:49
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Traws Pharma, Inc. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael Thomas CooperEdison Investment Research
Etzer DaroutGuggenheim Securities, LLC
Michael SchmidtGuggenheim Securities, LLC